Thermo Fisher to sell microbiology business to Astorg for $1.075B

Version 1

Thermo Fisher Scientific said on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to private equity firm Astorg for about $1.075 billion, made up of cash plus a $50 million seller note. The unit, which generated $645 million in 2025 revenue, supplies antimicrobial susceptibility testing and culture media for clinical, pharmaceutical, and food safety applications, and includes well-known brands such as Remel and Oxoid. Astorg said the business has about 2,400 employees, serves roughly 15,000 customers across more than 38,000 labs in over 100 countries, and will become an independent platform if the deal closes. Thermo Fisher expects the transaction to close in the second half of 2026, pending regulatory approvals. (ir.thermofisher.com)

Why it matters: For veterinary professionals, the headline isn't just corporate reshuffling. Culture media and susceptibility testing products sit inside routine diagnostic workflows that support animal health, food safety, and antimicrobial stewardship. A carve-out into a standalone company can bring more focused investment to microbiology, but it can also create near-term questions around distribution, technical support, contracting, and product roadmaps for labs and practices that rely on these systems. Astorg has framed the deal as a growth play centered on diagnostics and life sciences, while Thermo Fisher described it as part of active portfolio management. (astorg.com)

What to watch: Watch for regulatory clearance, any branding or channel changes for Remel and Oxoid, and whether Astorg uses the standalone platform to pursue follow-on acquisitions after the expected second-half 2026 close. (astorg.com)